Best Rx Most Cost-Effective: RTOG

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 12
Volume 15
Issue 12

In RTOG 9111, a randomized phase III trial in locally advanced laryngeal cancer, there was no difference in overall survival between the three arms, but disease-free survival, locoregional control, and preservation of the larynx were better in patients receiving induction chemotherapy plus radiation or concurrent chemoradiation, compared with radiation therapy alone.

PHILADELPHIA—In RTOG 9111, a randomized phase III trial in locally advanced laryngeal cancer, there was no difference in overall survival between the three arms, but disease-free survival, locoregional control, and preservation of the larynx were better in patients receiving induction chemotherapy plus radiation or concurrent chemoradiation, compared with radiation therapy alone.

In a subsequent economic analysis, based on 66 Medicare patients, "these better outcomes translated into significant savings of dollars spent on treating patients for complications and recurrences seen with the less effective therapy of radiation alone," Andre Konski, MD, MBA, of Fox Chase Cancer Center, said at the American Society for Therapeutic Radiology and Oncology 48th Annual Meeting (abstract 115). The expected mean 47-month cost of radiation alone was $57,357. Concurrent chemoradiation cost $57,870. Induction chemotherapy plus radiation was the most cost-effective. "At a 47-month cost of $49,018, this treatment saved $7,031 per disease-free life-year and $9,336 per life-year of overall survival, compared with radiation alone," Dr. Konski said.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
Treatment with toripalimab does not yield the same vascular toxicity seen with pembrolizumab in patients with advanced or metastatic nasopharyngeal carcinoma, according to Barbara Burtness, MD.
Overall survival also appears to improve with toripalimab compared with chemotherapy among patients with metastatic or advanced nasopharyngeal carcinoma.
head and neck cancer
head and neck cancer
Related Content